A multicentre, randomised controlled trial of PDSAFE, a physiotherapist-delivered fall prevention programme for people with Parkinson’s by Chivers Seymour, K et al.
1 
 
A multicentre, randomised controlled trial of PDSAFE, a physiotherapist-delivered 
fall prevention programme for people with Parkinson’s   
 
Kim Chivers Seymour1 (Trial Manager/Senior Research Fellow), Ruth Pickering2 (Professor Medical 
Statistics), Lynn Rochester3 (Professor of Human Movement Science and Director of Clinical Ageing 
Research Unit), Helen C Roberts2 (Professor of Medicine for Older People), Claire Ballinger2 (Wessex Public 
Involvement Network (PIN) Strategic Lead), Sophia Hulbert1 (Research Fellow), Dorit Kunkel1 (Senior 
Research Fellow), Ioana Marian2 (Statistician), Carolyn Fitton1 (Research Fellow), Emma McIntosh4 
(Professor of Health Economics), Victoria A Goodwin5 (Associate Professor of Ageing and Rehabilitation), 
Alice Nieuwboer6 (Professor of Rehabilitation Sciences), Sarah E Lamb7 (Director of Oxford Clinical Trials 
Research Unit), and Ann Ashburn*1 (Professor of Rehabilitation).  
 
* Corresponding author - ann@soton.ac.uk / Professor Ashburn/ 023 8120 6469 
1 Faculty of Health Science, University of Southampton, Southampton UK 
2 Faculty of Medicine, University of Southampton, Southampton, UK 
3 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK  
4 Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, University of 
Glasgow, Glasgow, G12 8RZ, UK 
5 College of Medicine and Health, University of Exeter, Exeter, EX1 2LU UK  
6 Department of Rehabilitation Sciences, KU Leuven, 3001 Leuven, Belgium 
7 Oxford Clinical Trials Research Unit, University of Oxford Medical Sciences Division, Oxford, OX3 7LD, UK 
 
 
 
References 41 
Word count Introduction to conclusion – 4325 words 
Abstract -252 words 
2 
 
ABSTRACT   
Objective: To estimate the effect of a physiotherapist-delivered fall-prevention programme for people with 
Parkinson’s (PwP).  
Methods: People at risk of falls with confirmed Parkinson’s were recruited to this multi-centre, pragmatic, 
investigator blind, individually randomised controlled trial with pre-specified sub-group analyses. 474 PwP 
(Hoehn and Yahr 1-4) were randomised: 238 allocated to a physiotherapy programme and 236 to control. 
All participants had routine care; the control group received a DVD about Parkinson’s and single advice 
session at trial completion. The intervention group (PDSAFE) had an individually tailored, progressive 
home-based fall-avoidance strategy training programme with balance and strengthening exercises.   
The primary outcome was risk of repeat-falling, collected by self-report monthly diaries, 0 to 6 months 
post-randomisation. Secondary outcomes included, Mini-BESTest for balance, chair stand test, Falls 
Efficacy, freezing of gait, health related quality of life (Euroqol EQ-5D), Geriatric Depression Scale, Physical 
Activity Scale for the Elderly and Parkinson’s disease Questionnaire, fractures and rate of near-falling. 
Results: Average age, 72 years and 266 (56%) were men. By 6 months 116 (55%) of the control group, and 
125 (61.5%) of the intervention group reported repeat falls (controlled odds ratio 1.21, 95% confidence 
interval 0.74 to 1.98, P=0.447).  Secondary sub-group analyses suggested a different response to the 
intervention between moderate and severe disease severity groups. Balance, falls efficacy and chair stand 
time improved with near-falls reduced in the intervention arm. 
Conclusion: PDSAFE did not reduce falling in this pragmatic trial of PwP.  Other functional tasks improved 
and reduced fall rates were apparent among those with moderate disease.  
Trial registration: Trial registration reference is ISRCTN48152791. 
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INTRODUCTION  
Parkinson’s disease is a progressive neurological condition that affects more than 10 million people 
worldwide; falls are common in this group. Prior to the start of the PDSAFE trial, a meta-analysis of fall 
reduction among the general older populatio[1] demonstrated a positive exercise effect but it was not until 
during PDSAFE that a meta-analysis of fall prevention among PwP was published[2]; findings were 
inconsistent with small overall effect sizes on fall rate ratios and group-based training more favourable 
than home-based interventions[3-8].   
 
Falls are twice as common among PwP as the healthy aged[1, 7-10]. Impairments of gait, including freezing 
of gait, cognition and loss of postural control are common risk factors for falling in this population, balance 
and falls are not easily remedied by medication[11, 12]. The effects of falls in PwP can be profound 
including loss of mobility, poor function in activities of daily living, fractures and increased care needs[7-9, 
12-13] as well as being costly to both individuals and health services[14]. There is some evidence that 
exercise may be useful for falls prevention in PwP[2]. However, trials conducted to date have usually been 
small, only 6 out of 25 trials in the meta-analysis recruited 100 or more participants. Most of the larger 
trials were negative[2] but there were differences in sub-group responses[6 ,7, 8]; benefits were 
demonstrated in higher functioning groups, particularly in people who had sufficient function to enable 
them to travel to exercise venues and participate in group programmes[6]. Canning at el[6] recruited 231 
PwP to an RCT and reported non-significant overall effect but significant interaction with disease severity; 
those with more severe disease had a greater number of falls following intervention, while there was 
significant improvement for those with less severe disease. 
 
Our aim was to compare the effect on repeat falling outcomes and other outcomes of an individualised, 
progressive exercise intervention delivered in people’s own home, in addition to usual care. We aimed to 
recruit a large, pragmatic sample of PwP, and used pre-specified and exploratory sub-group analysis to 
examine variation in the intervention effect according to baseline disease severity and freezing of gait.  
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METHODS 
Study design 
A full protocol has been published[15].  This was a multi-centre, pragmatic, investigator masked 
randomised controlled trial.  Participants were recruited from Parkinson’s services in NHS hospital and 
clinics, community and social services in eight regions across England: Bournemouth and Poole, Truro, 
Plymouth, Exeter, Winchester and Basingstoke, Newcastle, Portsmouth and Southampton. We also 
identified recruits via the study web-site. We delivered interventions in the participant’s home. The 
primary endpoint for the trial was 6 months after randomisation. We received funding to allow 12 month 
follow up on the first 342 recruited into the trial. An economic evaluation and a nested qualitative study of 
the views of participants will be published elsewhere as will details of the intervention. Trial management, 
data monitoring and statistical analyses were coordinated at the PDSAFE Trial office, University of 
Southampton, UK and supported by the Oxford Clinical Trials Unit OCTRU. Ethics approval was granted by 
the NRES South Central Hampshire B Committee (REC reference 14/SC/0039). Trial registration number is 
ISRCTN48152791. 
 
Participants 
People were eligible if they had a clinically confirmed diagnosis of Parkinson’s disease in accordance with UK 
Brain Bank criteria[16]; were living in their own home; independently mobile with or without an aid; 
experienced at least 1 fall in the previous 12 months; scored 24 or more on Mini-Mental State Examination 
[17] (MMSE); had the cognitive ability to give informed consent; were able to understand and follow 
commands; and considered able to participate in an exercise and strategy programme.  
 
Interventions 
All participants continued to receive usual care including medication management, and took part in their 
usual activities, such as exercise or social groups. Participants assigned to the control group were given a 
Parkinson’s UK DVD with information about Parkinson’s. At the end of their time in the trial, control 
participants received a single session on fall avoidance and a booklet on falls management.                                                                         
PDSAFE[18] comprised individually tailored, progressive home-based exercise and strategies to avoid falls 
eg. ‘Stepping patterns and sideways stepping in small complex areas to avoid tripping’. Registered 
physiotherapists made visits to the participants’ home to provide 12 supervised sessions of 1 to 1.5 hours 
duration over 6 months.  More supervised sessions were delivered early in the programme, and gradually 
tapered over time. From the start of the programme, participants were expected to engage in daily, 
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unsupervised exercise for about 30 minutes, and were provided with a prescription for these and strategies 
to maximise adherence, such as integration into daily routines.  Participants were given a folder with 
pictures and descriptions of exercises, a rating of perceived exertion scale, an exercise log, and DVDs of 
both exercise demonstrations and personal videos taken by their physiotherapist of them doing the 
exercises. Programmes were based on an individualised assessment of fall risk factors, including the home 
environment and high-risk activities.  Exercises included balance training with a gradual decrease in the 
area of support and use of foam standing pads. Strength training used body weight resistance, and if 
appropriate, weighted vests, during functional exercises (sit to stand). Strategies for fall and freezing 
avoidance included transfer practice (turning) in complex environments such as bathrooms and kitchen and 
adopting wide-based positions during functional task practice.   
Intervention fidelity was promoted through a two-day training session, and subsequent observation and 
feedback during sessions by a specialist physiotherapist with expertise in Parkinson’s management All but 
one physiotherapist had a background in neurological practice. Monthly ‘master classes’, weekly 
teleconferences and regular clinical supervision sessions were implemented. Fidelity checks were 
undertaken three times during a therapist’s first three months of delivering the intervention, and three 
monthly thereafter. We considered that people who attended the assessment and received one home 
session to have engaged with the intervention. Those who had 7 or more sessions were considered to have 
complied with the intervention.  
 
Outcomes 
The primary outcome was risk of repeat falling in the first six months after randomisation.  A fall was 
defined as an event which resulted in a person coming to rest unintentionally on the ground or lower 
level[19].  Secondary outcomes were fractures and the rate of near falling, the Mini-BESTest[20] (high 
values – good, a test of balance control); the chair stand test[21] (low timing - good) ; medication use; the 
Geriatric Depression Scale, GDS[22] (15 question version; low scores - good); the International version of 
the Falls Efficacy Scale, FES[23] (low scores - good); the New Freezing of Gait questionnaire, NFoG[24] (low 
scores - good); the Parkinson’s Disease Questionnaire, PDQ-39[25] (low scores - good, a quality of life 
measure designed specifically for PwP); the Physical Activity Scale for the Elderly, PASE[26]; high scores - 
good) at 6 months; the Euroqol (EQ5D 3L) health related quality of life instrument[27]. We recorded all 
deaths, any hospitalisations were recorded at assessment and serious adverse events were reviewed by 
medical physician, HR. The PASE, PDQ-39 and GDS were self-completed and returned by post. 
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Randomisation and blinding 
Prior to randomisation, participants completed three months of fall diaries. We then did a baseline 
assessment after which participants were randomly assigned (50:50) to either the intervention or control 
group, using an online procedure set up by OCTRU (a UKCRC registered trials unit). The allocations were 
sent to the trial manager who informed a treating therapist, to ensure allocation concealment from trial 
recruiters and assessors. Random allocations were computer-generated, stratified by centre and allocated 
in blocks with random size of 2, 4, 6 or 8. The trial manager, the treating therapists and the participants 
were not blinded to the allocated group. At each point of contact, participants were asked not to divulge 
their group allocation to trial assessors who were blind to group allocation. 
 
Procedure 
We trained registered health care professionals to assess eligibility of potential participants, to register and 
randomise participants, to collect baseline information and administer outcome measures during the 
follow up period; fidelity checks were routinely made. We collected eligibility and baseline data over two 
visits, separated by a three month period in which we asked participants to collects falls diary data. At the 
first eligibility visit we collected the Montreal Cognitive Assessment (MoCA)[28], the number of falls 
experienced over the previous 12 months, the Mini-Mental State Examination (MMSE)[17], the Hoehn & 
Yahr Scale of Disease severity[29], demographics and medical history. At the second visit, we re-checked 
consent, collected the Unified Parkinson’s disease Rating Scale, UPDRS[30] (low scores - good, motor 
section only) and enrolled and randomised the participant. Participants were asked to complete monthly 
diaries through the follow up period and face to face assessments were taken to collect all other data 
during home visits at 6 and, for those completing the extend follow up, at 12 months.   
 
Sample size calculation  
Based on the results of a previous trial[8] we assumed the risk of repeat falling between 0 and 6 to be 50% 
in the intervention group and 63% in the control group, yielding a sample size requirement of 228 
participants per group at 80% power in a two-sided 5% comparison of proportions. Allowing for 15% (10% 
before randomisation and 5% after) loss to follow up, for these participants, between approach, 
randomisation and 6 months, we aimed to recruit 534 participants to the pre-randomisation falls collection 
period. 
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Statistical analysis  
A statistical analysis plan was finalised before the dataset was locked. The analysis was intention to treat in 
that all participants were analysed in the group to which they were randomised. For the primary outcome 
we included participants who had completed a minimum of 50% of diaries, (as recommended by Goodwin 
et al[7]) and missing falls diary data, for these participants, by imputing the binary indicator of repeat faller 
(yes/no) from the final assessment if this data were available. The analysis of rates of falling included all 
participants with any degree of diary completion.  
 
We used logistic regression controlling for site, age, gender, Hoehn and Yahr, the logarithm of 
retrospectively collected number of falls in the year prior to screening, repeat fall status prior screening, 
and the logarithm of the prospectively collected rate of falling during the 3 months period prior to 
randomisation with 0.5 added to numerators so that participants with zero falls during the period were 
included. These controlling variables were finalised in a blind analysis without access to the group 
indicator, as specified in the analysis plan. Rates of falling during the periods 0 to 6 and 6 to 12 months post 
randomisation were examined in negative binomial models with the logarithm of a participant’s days of 
diary follow-up included as an offset. Odds Ratios (OR) and Fall Rate Ratios (FRR) are presented with 95% 
confidence intervals (CI). The geometric mean of individual participant rates (with 0.5 added to the 
numerator as before) of falling during 6 month follow-up periods are presented as rates per 6 months to 
accommodate the skewed distribution across participants. We pre-specified subgroup analysis for falling 
between 0 and 6 months to MoCA[28] status (≤25 and ≥26), freezing status, and disease severity 
UPDRS[30] and Hoehn and Yahr [29]. In addition,  and informed by the findings of Morris et al[3,5] we 
explored sub-group analyses for MoCA, UPDRS and number of falls in the year prior to screening using the 
tertiles of the baseline distribution. We tested for sub-group effects using statistical tests of interaction. A 
secondary per protocol analysis excluded participants from the PDSAFE group who received less than 7 of 
the planned 12 sessions. Analysis was conducted in SPSS (IBM Corp., Armonk, NY) and Stata[31]. 
 
Patient Involvement 
PPI representatives were involved in the design of the study, the development of participant information 
sheets, consent forms and intervention resources. A PPI representative was a member of the Trial Steering 
Committee. The trial was discussed at several Local Parkinson’s support groups and representatives were 
invited to a meeting on interpretation of results and key messages.  
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RESULTS 
Trial progression and recruitment 
Recruitment was from July 2014 to August 2016 (study flow summarised in Figure 1). A total of 640 PwP 
were invited to participate, 99 either did not respond or did not meet the eligibility criteria leaving 541 for 
consent and completion of the first eligibility visit. At this point, a further 7 people did not reach the MMSE 
requirement and were excluded. The remainder went on to second eligibility check after which a further 60 
people were excluded (reasons provided in Figure 1). The remaining 474 completed a baseline assessment 
and were randomised to usual care (n= 236) or PDSAFE (n= 238). Withdrawal rates were low at the primary 
time point, and equivalent across the groups. Falls diary completion was good at the primary time point, 
with 203/238 (85%) of the usual care group, and 211/236 (89%) of the intervention group providing usable 
data, see supplementary table. The IQR for the number of diary completion days over the primary 6 month 
period were 174-183 and 153-183 days in the control and intervention groups respectively. Fourteen 
trained assessors completed blinded data collection. 
 
Intervention 
Eighteen physiotherapists delivered PDSAFE and compliance with the intervention was good. 217/238 
(91%) participants received per protocol, 7 or more supervised treatment sessions and 75% (162) of those 
received the maximum number. The median number of supervised sessions for all participants randomised 
to the intervention was 12 (IQR 11 to 12). The majority of participants, 236/238, received the exercise 
assessment and at least one supervised session. Two participants did not start due to a change of mind, 19 
received less than 7 sessions. Reasons for withdrawal from the trial included: admission to a nursing home, 
deteriorating health, commitment was too much, no reason given and caring for others (see figure 1).  
 
Figure 1 
 
Sample 
The baseline characteristics of randomised groups were balanced (Table 1). There was a difference in the 
rate of falling in the run-in-period.  
 
Table 1 
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Table 2 
 
 
Outcomes 
There was little difference in the rate of falling between groups in the first 6 months (Table 2). Table 3 
shows the treatment effect estimates for the primary time point including the primary outcome. Repeat 
falling in the PDSAFE group at 6 months was slightly higher than in the control group (OR 1.21 (95% CI 0.74 
to 1.98, P=0.447)). There was significantly lower risk of near falling (0.67, (95% CI 0.53 to 0.86, P=0.001)) in 
the PDSAFE compared to control group. 
 
Tables 3 & 4 
 
For the secondary outcomes collected at 6 months (table 3), the exercise group had better balance 
(between group difference Mini-BEST score 0.95 points (95% CI 0.24 to 1.67 P=0.009); better falls 
confidence (between group difference 1.60 points (95% CI 3.00 to 0.19, P=0.026); and improved balance 
and functional strength as assessed by the Chair stand test, CST (P=0.041) (table 4). No material differences 
from those reported above were found when analyses were repeated on a per protocol basis. 
 
Fig 2 
 
 
Pre-specified and exploratory sub-group analysis - 6 months 
The results of pre-specified sub-group analyses for MoCA and freezing of gait are shown in Figure 2, along 
with further analysis of subgroups defined by tertiles. People who had freezing of gait at study entry did 
not respond well to the intervention, and this interaction effect estimate was statistically significant 
(P=0.025) There were trends toward worse response to treatment in people with cognitive impairment (as 
measured by the MoCA) (P=0.111 and P=0.088 for the analyses of repeat falls and rate of falling 
respectively).   
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Statistically significant differences in the PDSAFE effect in relation to rate of falling were found across 
subgroups according to UPDRS severity, and retrospectively collected falling in the year prior to screening 
(interaction P=0.009 and 0.050 respectively); with an indication of possible benefit of PDSAFE in the middle 
subgroups only, while PDSAFE was associated with increased rate of falling in the most severe group. The 
impact of PDSAFE on near falling, Mini-BESTest and falls confidence was consistently beneficial across the 
subgroups. 
 
Adverse events and deaths 
Two participants died during follow-up in the PDSAFE group and five in the control group (figure 1). During 
the 6 months following randomisation, five fractures were reported by PDSAFE and nine by control group 
participants. Nine PDSAFE and twenty control group participants reported hospitalisations, of whom one 
PDSAFE participant reported two stays, none of these were associated with participation in the 
intervention.  
 
Extended follow up 
During the period 6 to 12 months after randomisation, seven fractures were reported by PDSAFE and three 
by control group participants; eighteen PDSAFE and 21 control group participants reported hospitalizations 
of whom two PDSAFE and four control participants reported two hospital stays. No participant fell during 
exercising. 
 
DISCUSSION 
PDSAFE is the largest trial of physiotherapy for fall prevention among PwP, with 474 participants 
randomised it was more than double the size of the previous largest trial by Canning et al[6] with 231 
participants. It was novel with a personalised intervention conducted in the home-setting, and both a 
three-month pre-randomisation baseline and follow-up counts of falls collected prospectively in diaries. 
Despite this, we failed to demonstrate PDSAFE was effective in reducing falls in a heterogeneous sample of 
PwP overall.  Our non-significant result was similar to that found by previous researchers of trials with 
more than 100 participants[5, 6, 7, and 8] and falls as a primary outcome. The exception was a trial of 
exercises, conducted in an out-patient setting by Morris et al in 2015[3], this positive outcome was not 
replicated when repeated at home with a lower treatment dose[5]. Two other research groups reported 
falls reduction as a result of interventions outside of current physiotherapy; virtual reality and treadmill 
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training[4] and Tai Chi[32].  A meta-analysis of falls interventions prior to this trial demonstrated an 
inconsistency of effect with a need for higher quality trials[2].  In line with those previous researchers of 
non-significant trials we found a diverse response to the intervention, those with milder disease 
responding better to the intervention than those with a more severe condition profile. 
It has been suggested that non-significant fall prevention trials have resulted from under dosing of 
treatment[3] but dosing rehabilitation is complex. Rehabilitation is an interactive educational process 
designed to improve function and facilitated by a therapist. Each person has to actively participate in 
rehabilitation, the process of which can be influenced by motivation, age, cognition and severity of 
condition. Other important features are timing and content of intervention as well as the therapists and 
training. We will address these issues below and discuss how they may have led to the non-significant 
finding of our trial. 
First, the influence of the therapy content and delivery on rehabilitation dose.  A strength of the trial was 
the evidence-based therapy programme delivered by skilled trained physiotherapists. The PDSAFE training 
was structured and practice was rigorously tested for fidelity.  Ninety-one percent of the intervention-
group participants received per protocol, on average 12 face-to-face supervised sessions of 1 to 1.5 hours 
and were encouraged to complete unsupervised daily practice, meeting the recommendations of 
Sherrington et al[33] of at least 50 hours of practice. Previous researchers have used a range of different 
interventions, often poorly described with a great deal of diversity of treatment protocols and dosage. The 
PDSAFE trial delivered more supervised sessions than any of the other five identified research trials, e.g.: 
one hour weekly face to face for six weeks[5], one hour weekly group sessions for 8 weeks[6], and one 
hour weekly group session for 10 weeks[7], one hour monthly group session for 6 month, one hour weekly 
session for 6 weeks[8], in addition all encouraged independent practice but their recommendations were 
not as frequent as the PDSAFE mandate of daily routine.  In terms of amount of treatment a balance is 
needed between sufficient time for training and too high an expectation of commitment, if too high 
participants start to withdraw and even under our procedures we had a greater withdrawal from the 
intervention group than our control group. Our programme was personalised in order to maximise 
individual motivation and it was multidimensional, requiring individuals to progress their activities and to 
integrate their training into everyday functional tasks which needed active participation from them and 
cognitive reasoning but this may have been too challenging for some. While manageable by those in the 
moderate to least severe disease groups, attention, reaction and response rates may have been 
compromised at the more severe end of the spectrum even though the treatment and selection of tasks 
were personalised.                             
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Second, the influence of individual characteristics on rehabilitation dose.  Our sample reflected a typical 
heterogeneous Parkinson’s population and was not dissimilar to the other research trials, it comprised 
participants with a range of disease severity and fall events; at least one fall in the previous 12 months, 
some with multiple falls and high disease severity or more complex symptoms, such as freezing. Within 
Parkinson’s, falls are indicative of a changing disease process; PwP with an established pattern of falling will 
have more global features of decline of age and/or disease association, Lord et al[34] suggest these 
progressive features create additional challenges for implementing appropriate management and research. 
Our sample typically included those with and without freezing of gait and, although we screened to exclude 
individuals with cognitive impairment using the MMSE[17], some participants at baseline and subsequent 
assessments scored low on the MoCA[28], a test known to be sensitive to frontal and executive function 
associated with people who fall[35]. The motor learning potential is reduced in people who freeze[36,37] 
and are cognitively challenged; increasing evidence demonstrate that freezing of gait is an important risk 
factor of falls, associated with reduced balance[38] and impaired cognition. The inclusion of people who 
did or did not experience freezing illustrates the diverse range of motor problems present in a community 
sample of PwP and the range of challenges faced when teaching and learning new skills. Domingeos et 
al[39] have called for more studies into fall prevention with people with impaired cognition. 
That exercise is not uniformly effective across all presentation of Parkinson’s had been suggested but not 
confirmed in three previous smaller trials[6, 7, 8], this informed our decision to pre-specify and undertake 
sub-group analyses on our data.  The recent work of Canning et al 2016[6] and older trials by Goodwin et al 
2011[7] and Ashburn et al 2007[8] consistently found in their secondary analysis that those with less severe 
Parkinson’s responded positively to fall reduction programmes but that effect had been counterbalanced 
with deterioration among those at the worse end of the spectrum producing a non-significant overall 
result.  Although we have a number of sub-group analyses in PDSAFE, the results are consistent with other 
published estimates reflecting a similar pattern: those in the moderate disease group, and in the middle 
group with respect to number of falls prior to the trial had a positive effect from PDSAFE with a 30% 
reduction in FRR (95% confidence interval 50% to 5% reduction) in the first six months following 
randomisation. However, there was an increase in FRR of 43% (95% confidence interval 4% to 95% helpful 
for the moderate disease group, more or different supervised therapy may have been required for those 
with freezing of gait and greater disease severity (more likely to have additional cognitive impairment) as 
they could have been more challenged by fall avoidance strategies and experienced greater difficulty with 
engaging in unsupervised sessions, thus limiting the intensity of practice and the effects.   
A number of previous trials[2] have shown the benefits of exercise on risk factors for falling. In PDSAFE 
balance, functional strength and falls efficacy were targeted in the treatment and our analysis of secondary 
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outcomes demonstrated a consistent improvement across the whole PDSAFE group i.e., those with mild, 
moderate and severe disease. These results support those of others[2] highlighting the positive effects of 
exercise for balance and gait ability. Interventions in previous trials have largely been delivered outside the 
home setting but our current results demonstrate similar findings from interventions within the home 
environment. A positive PDSAFE effect on near-falls, an indicator of instability and reflective of the 
improvements in balance, was also reported.  Near-falls among PwP have been reported by Gazibara et 
al[40] and Ashburn et al[8] and are often related to stumbling or balance loss and have been observed to 
predispose falling in the general older population[41].  As previously highlighted, all participants, even 
those with cognitive impairments, greater disease severity and freezing of gait showed improvements in 
their balance scores and fall efficacy scales. We suggest this indicates these participants were able to 
comply with exercise but were not able to benefit from the more demanding fall prevention programme 
possibly because of the need to react and respond in a timely way at moments of instability.  
A limitation of our research was the incomplete 12 month assessment on our sample, a consequence of 
restricted funding. All participants in our trial were followed to six months, the point of primary outcome 
but the last 132 recruits could not be followed to one year post-randomisation resulting in a smaller 
sample at 12 months impacting on the interpretation of long-term follow-up, including the economic 
evaluation.  
 
CONCLUSION  
PDSAFE did not reduce falls in the overall heterogeneous sample of PwP. The treatments were 
personalised to individual needs within the structure of the PDSAFE concept but the package may not have 
adequately addressed the range of profiles across the disease spectrum. Those with more severe disease 
may have found implementing the fall avoidance movement strategies too challenging or they needed 
more training time; secondary analysis showed diverse responses to the intervention. Secondary outcome 
measures demonstrated improvement in balance, functional strength and falls efficacy with a reduction in 
near-falls across the whole sample. Further confirmatory trials of falls prevention on targeted groups of 
PwP are recommended.  
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Figure Legends: 
Figure 1 Flow of Participants through the Trial 
 
Figure 2 Overall and subgroup analysis of falling, near-falling (during 0-6 months) and secondary outcomes 
(at 6 months). 
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Table 1: Baseline characteristics in the PDSAFE and control groups: figures are 
number (%) unless stated otherwise 
  PDSAFE 
(n=2381) 
Control 
(n=2362) 
Gender  
 
 male 
female 
147 (62%) 
 91 (38%) 
119 (50%) 
117 (50%) 
Age (years)  mean (SD) 
min to max 
71 (7.7) 
51 to 91 
73 (7.7) 
46 to 88 
Disease duration (years) mean (SD) 
min to max 
8 (6.6) 
0 to 36 
8 (5.8) 
0 to 29 
MMSE mean (SD) 
min to max 
28 (1.7) 
24 to 30 
29 (1.6) 
24 to 30 
MoCA mean (SD) 
min to max  
≤ 25 (cognitively impaired) 
26 (2.9) 
15 to 30 
91 (38%) 
26 (3.2) 
9 to 30 
93 (39%) 
Living status lived alone 
with a spouse/partner 
with a friend/family 
48 (20%) 
174 (73%) 
15 (6%) 
59 (25%) 
166 (70%) 
10 (4%) 
Hoehn and Yahr stage  1 
2 
3 
4 
26 (11%) 
78 (33%) 
102 (43%) 
32 (13%) 
30 (13%) 
56 (24%) 
112 (48%) 
38 (16%) 
UPDRS  mean (SD) 
min to max 
TD phenotype 
PIGD phenotype 
indeterminate 
32 (15.2) 
2 to 77 
21 (9%) 
194 (83%) 
20 (8%) 
33 (17.3) 
4 to 92 
19 (8%) 
206 (88%) 
10 (4%) 
Freezing of gait in the past month 152 (64%) 139 (59%) 
No. of falls in 12 
months prior to 
screening 
median (min to max) 
mean (SD) 
repeat falling in 12 months 
3 (1 to 1460) 
26 (132.7) 
186 (78%) 
3 (1 to 1095) 
19 (105.4) 
189 (80%) 
Rate of falls/person/3 months 
prior to randomisation 
median (min to max) 
mean (SD) 
1.98 (0 to 319) 
5.9 (22.8) 
0.99 (0 to 73) 
3.0 (7.3) 
Rate of near falls/person/3 months 
prior to randomisation 
median (min to max) 
mean (SD) 
4.4 (0 to 440) 
13.8 (35.8) 
4.3 (0 to 601) 
15.6 (51.4) 
Medications 
 
Levodopa 
Dopamine agonist 
Monoamine oxidase inhibitor 
COMT inhibitors 
other PD medication 
208 (88%) 
108 (46%) 
52 (22%) 
59 (25%) 
19 (8%) 
216 (92%) 
106 (45%) 
46 (20%) 
41 (17%) 
23 (10%) 
GDS score at baseline  > 5 (suggestive of depression) 
≥ 10 (indicative of depression) 
147/235 (63%) 
50/235 (21%) 
164/236 (70%) 
49/236 (21%) 
Coexisting conditions  orthopaedic 
Cardio/Respiratory 
109 (46%) 
85 (36%) 
129 (54%) 
96 (41%) 
1Missing values in the intervention group: living status (1); UPDRS (1); disease duration (1); freezing of gait 
(1); rate of falling in the 3 months prior to randomisation (1); TD/PIGD/ Indeterminate phenotype (3). 
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2Missing values in the control group: living status (1); UPDRS (1); TD/PIGD/ Indeterminate phenotype (1). 
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Table 2: Intention-to- treat analysis of falling outcomes: 0 to 6 and 6 to 12 months 
Period 
PDSAFE Control PDSAFE/control*  
OR (95% CI) P* Number (%) 
Repeat falling 
restricted to ≥50% 
diaries 
baseline 127/231 (55%) 92/230 (40%)   
baseline** 112/203 (55%) 80/211 (38%)   
0-6 months 125/203 (62%) 116/211 (55%) 1.21 (0.74, 1.98) 0.447 
baseline** 55/114 (48%) 47/132 (36%)   
6-12 months 57/114 (50%) 71/132 (54%) 0.86 (0.45, 1.65) 0.657 
 Falls/person/6 months*** FRR (95% CI)  
Fall rates baseline 4.5 3.3   
0-6 months 3.4 2.7 0.98 (0.80, 1.19) 0.824 
6-12 months 2.7 2.8 0.83 (0.62, 1.11) 0.200 
  Near falls/person/6 months*** NFRR (95% CI)  
Near fall rates baseline 8.0 8.1   
0-6 months 4.7 5.6 0.67 (0.53, 0.86) 0.001 
6-12 months 3.9 3.7 1.01 (0.67, 1.52) 0.968 
* Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in 
the year prior to screening, log rate of falling in the pre randomisation falls collection period, and Hoehn 
and Yahr (NFRR additionally controlled for log rate of near falling in the pre randomisation falls collection 
period).  
** Baseline repeat falling restricted to participants including in the 0-6 and 6-12month analyses 
*** Geometric mean of individual fall rates with 0.5 added to all numerators 
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Table 3: Secondary outcomes at 6 and 12 months  
  mean (SD, n) mean difference 
(PDSAFE -Control) 
(95% CI)* P* 
 
visit 
PDSAFE 
(n=238) 
Control 
(n=236) 
MiniBESTest 
(0-28, lower 
values worse) 
 
**baseline 
6 months 
6 months-baseline 
18.3 (5.7, n=183) 
19.4 (5.9, n=183) 
1.1 (3.8, n=183) 
17.3 (6.1, n=211) 
17.5 (6.4, n=211) 
0.2 (3.8, n=211) 
 
 
0.95 (0.24, 1.67) 
 
 
0.009 
***baseline 
12 months 
12 months-baseline 
18.5 (5.8, n=115) 
17.9 (6.5, n=115) 
-0.7 (4.5, n=115 ) 
17.5 (6.1, n=126) 
17.4 (6.7, n=126) 
-0.2 (3.8, n=126) 
 
 
-0.41 (-1.48, 0.66) 
 
 
0.449 
FES-I 
(16-64, higher 
values worse) 
**baseline 
6 months 
6 months-baseline 
34.1 (11.0, n=189) 
33.4 (10.6, n=189) 
-0.7 (7.9, n=189) 
35.1 (11.5, n=211) 
36.2 (11.4, n=211) 
1.1 (7.2, n=211) 
 
 
-1.6 (-3.0, -0.19) 
 
 
0.026 
***baseline 
12 months 
12 months-baseline 
33.4 (10.7, n=119) 
34.8 (11.2, n=119) 
1.3 (8.2, n=119) 
33.7 (11.3, n=135) 
37.2 (11.6, n=135) 
3.5 (9.3, n=135) 
 
 
-1.4 (-3.41, 0.66) 
 
 
0.184 
PASE 
(0-400, lower 
values worse) 
**baseline 
6 months 
6 months-baseline 
107.8 (73.5, n=153) 
110.2 (70.4, n=153) 
2.4 (50.8, n=153) 
100.1 (67.1, n=177) 
100.6 (68.0, n=177) 
0.5 (49.5, n=177) 
 
 
-1.05 (-11.3, 9.21) 
 
 
0.841 
***baseline 
12 months 
12 months-baseline 
108.1 (71.9, n=98 ) 
99.4 (72.8, n=98) 
-8.7 (53.0, n=98) 
98.6 (61.1, n=115) 
87.6 (62.3, n=115) 
-11.0 (48.5, n=115) 
 
 
-0.55 (-13.9, 12.8) 
 
 
0.935 
PDQ39  
(0-100, higher 
values worse) 
**baseline 
6 months 
6 months-baseline 
27.4 (14.3, n=126) 
28.3 (15.0, n=126) 
0.8 (8.3, n=126) 
28.7 (15.9, n= 153) 
29.5 (16.5, n= 153) 
0.9 (9.0, n= 153) 
 
 
0.12 (-2.0, 2.28) 
 
 
0.911 
***baseline 
12 months 
12 months-baseline 
27.2 (13.6, n=77) 
29.1 (15.4, n=77) 
1.9 (8.6, n=77) 
28.9 (15.9, n=100) 
31.7 (15.5, n=100) 
2.8 (11.2, n=100) 
 
 
0.48 (-2.53, 3.49) 
 
 
0.754 
GDS 
(0-15, higher 
values worse) 
**baseline 
6 months 
6 months-baseline 
7.7 (2.3, n=154) 
7.8 (2.5, n=154) 
 0.3 (1.8, n=154) 
7.7 (2.1, n=183) 
8.0 (2.5, n=183) 
0.2 (1.9, n=183) 
 
 
-0.02 (-0.42, 0.39) 
 
 
0.942 
***baseline 
12 months 
12 months-baseline 
7.7 (2.1, n=96) 
7.8 (2.5, n=96) 
0.2 (2.0, n=96) 
8.0 (2.2, n=118) 
8.5 (2.4, n=118) 
0.4 (1.7, n=118) 
 
 
-0.21 (-0.72, 0.31) 
 
 
0.421 
* Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior 
to falling, log rate of falling in the pre randomisation falls collection period, Hoehn and Yahr, and the outcome in 
question assessed at baseline. 
** Baseline results restricted to existing participant assessment at 6 months  
*** Baseline results restricted to existing participant assessment at 6 months 
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Table 4: Chair Stand Test (CST) at 6 and 12 months 
 PDSAFE 
(n=238) 
Control 
(n=236) P* 
Baseline amongst 
participants with 
6 month 
assessment  
Unable of those with a CST assessment  29/188 (15%) 35/213 (16%)  
 
 
 
 
 
0.041 
(n=401) 
CST (seconds) 
amongst 
those able 
median     
IQR 
 
14 
11 to 18 
 (n=159) 
14 
11 to 18 
 (n=178) 
6 month 
assessment 
Unable of those with a CST assessment  27/188 (14%) 47/213 (22%) 
CST (seconds)  
amongst  
those able 
 median 
IQR 
 
12 
10 to 15 
 (n=161) 
13 
10 to 16 
 (n=166) 
Baseline amongst 
participants with 
12 month 
assessment 
Unable of those with a CST assessment 15/119 (13%) 21/134 (16%)  
 
 
 
 
 
0.163 
(n=253) 
CST (seconds) 
amongst  
those able 
median 
IQR 
 
14 
11 to 17 
 (n =104) 
14 
12 to 18 
 (n=113) 
12 month 
assessment 
Unable of those with a CST assessment 23/119 (19%) 38/134 (28%) 
CST (seconds) 
amongst 
those able 
median 
IQR 
 
12 
9 to 14 
 (n=96) 
13 
11 to 15 
 (n=96) 
* Mann Whitney U test incorporating participants unable to perform test and times from participants 
able to perform test. 
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Figure 2: Overall and subgroup analysis of falling, near falling (during 0 to 6 months) and secondary outcomes (at 6 
months) 
 
 
* Test for interaction of PDSAFE contrast differing across subgroups, controlled for site, age, gender, repeat falling or not in the year prior to screening, log 
number of falls in the year prior to falling, log rate of falling in the pre randomisation falls collection period, Hoehn and Yahr, and the outcome in question 
assessed at baseline. 
**OR= Odds Ratio; FRR=Falls Rate Ratio; NFRR= Near Falls Rate Ratio; Mini-BESTest= Balance Evaluation Systems Test; FES-I= Falls Efficacy Scale 
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